Business
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
SAN DIEGO, March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, March 28, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data on treatment patterns and unmet needs in adult and pediatric patients with classic congenital adrenal hyperplasia (CAH) at the Academy of Managed Care Pharmacy (AMCP) 2022 annual meeting in Chicago on March 29–April 1. The three studies being presented evaluate the treatment patterns, healthcare-related costs, medication preferences, and unmet needs of patients with classic CAH.\n\n \n \n \n \n \n \n\n \n\"There are currently no non-steroidal U.S. FDA-approved treatments for classic CAH, which means management of the condition can be challenging for patients and caregivers alike,\" said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. \"The data we are presenting at AMCP 2022 reinforce the challenges of managing classic CAH among patients living with this condition, with a treatment paradigm that has remained unchanged for more than 60 years. These studies underscore our commitment to improving the scientific and medical community's understanding of classic CAH and the limitations of the current standard of care, and are instrumental in guiding our efforts to advance new treatment options.\"\nClassic CAH due to 21-hydroxylase deficiency (21-OHD) is a rare autosomal recessive condition characterized by cortisol deficiency and elevated adrenocorticotropic hormone (ACTH) secretion, resulting in excess androgen production. The current standard of care is glucocorticoid (GC) therapy to replace endogenous cortisol deficiency; however, supraphysiologic GC doses are often needed to reduce elevated ACTH secretion and excess androgen production. Monitoring and titrating GC treatment remains a major clinical challenge due to the competing priorities of avoiding the clinical consequences of excess androgen from GC undertreatment, including accelerated growth before puberty that results in height below genetic potential, virilization and menstrual irregularities in females, testicular adrenal rest tumors in males, and fertility problems in both sexes in adulthood, while minimizing the risk of the well-recognized sequelae and complications of chronic GC overtreatment, including metabolic abnormalities, bone loss, growth impairment, and iatrogenic Cushing's syndrome.\nNeurocrine Biosciences ...